<DOC>
	<DOCNO>NCT00151775</DOCNO>
	<brief_summary>This study assess efficacy safety olmesartan medoxomil child age 1-16 high blood pressure . After 5-week blind treatment period 5 week participant continue take olmesartan medoxomil ( OM ) additional 46 week .</brief_summary>
	<brief_title>Assessment Efficacy Safety Olmesartan Medoxomil Children Adolescent Patients With High Blood Pressure</brief_title>
	<detailed_description>This randomize , multicenter , double-blind , parallel-group , prospective dose-ranging study subject 1 16 year age hypertension . Subjects enrol 1 3 cohort base age race . Subjects 6 16 year age enrol Cohort A . Subjects enrol Cohort A stratified age approximately half aged 6 12 year remainder age 13 16 year . Approximately 15 % subject Cohort A Black African descent . When minimum 28 Black subject randomize Cohort A , enrollment Cohort B start . Black subject , 6 16 year age , enrol Cohort B . For Cohorts A B body weight patient &gt; =20Kg . Seated systolic blood pressure ( SeSBP ) &gt; =95th percentile gender height-for-age , &gt; =90th percentile patient diabetic , glomerular kidney disease , family history hypertension . Patients symptomatic hypertension require immediate establish therapy , 2 standard deviation ( SD ) 99th percentile participate study . Subjects 1 5 year age enrol Cohort C regardless race . Body weight patient &gt; =5Kg . SeSBP &gt; =95th percentile gender height-for-age , &gt; =90th percentile patient diabetic , glomerular kidney disease , family history hypertension . Patients stable dos concomitant antihypertensive agent include calcium channel blocker and/or diuretic permit enroll . Patients symptomatic hypertension require immediate establish therapy , 2 SD 99th percentile participate study . The study comprise four period . Period I wash-out period Week -1 randomization . Subjects randomized treatment sequence carry remainder study . Period II three-week , double-blind , dose-ranging period Cohorts A B , begin Day 1 end end Week 3 . In Cohorts A B , subject receive either low-dose high-dose olmesartan ( OM ) daily . In Cohort C , Period II open-label OM treatment period subject receive 0.3 mg/kg OM per day . Period III double-blind , placebo-controlled withdrawal period begin Week 4 end 1 2 week , depend seat blood pressure measurement weekly study visit . Subjects either continued Period II OM regimen switch placebo base initial randomization scheme . Period IV 46-week open-label extension period .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Olmesartan</mesh_term>
	<mesh_term>Olmesartan Medoxomil</mesh_term>
	<criteria>The patient 's seat systolic BP ( SeSBP ) great equal 95th percentile gender heightfor age , great equal 90th percentile patient diabetic , glomerular kidney disease , family history hypertension . Negative hepatitis B C Negative HIV Patient serious condition could interfere analysis result could interfere wellbeing patient trial . Known sensitivity olmesartan medoxomil Taking prohibited medication Consumed great 180 mg caffeine daily Malignant hypertension History congestive heart failure , cardiomyopathy , obstructive valve disease Renal transplant within previous 6 month Severe nephritic syndrome remission</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>16 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Treatment hypertension high blood pressure child age 1-16 year .</keyword>
</DOC>